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Summary The effect of systemic therapy on tumour oestrogen receptor (ER) concentration has been studied
in 88 patients with large, operable, primary tumours (total 89) of the breast. In 26 patients, tumour was not
available for study on one occasion (usually post-treatment). Forty-five patients were treated initially by
endocrine therapy but, of these, 13 who had failed to respond went on to receive chemotherapy also.
Seventeen patients with low concentrations of ER (<20 fmol mg-' protein) were treated directly by
chemotherapy. Patients underwent an incisional biopsy for confirmation of diagnosis and determination of
pre-treatment ER by radioligand binding assay, followed by systemic therapy for 3 months (or 6 months for
both endocrine and cytotoxic therapies). Response was assessed clinically and mammographically before
mastectomy. ER concentration was then determined in the post-treatment tumour specimen. No significant
change in ER concentration was seen in any treatment group except when the patients had received tamoxifen;
there, receptor concentration fell to very low levels, presumably due to interference with the assay. There was
no relationship between tumour response to systemic treatment and change in ER concentration. It is
concluded that changes in ER concentration are unlikely to play a major role in the early response of breast
tumours to systemic therapy.
Studies of the effect of therapy on the oestrogen receptor
(ER) concentration of breast cancer have previously relied
upon examination of different tumour deposits (Taylor et al.,
1982; Hamm & Allegra, 1988). Since these deposits may
differ in biological characteristics, including the concentration
of ER (Hoehn et al., 1979; Hawkins et al., 1981), this may
lead to erroneous conclusions. We have previously reported
the treatment of patients with large operable breast cancers
by primary systemic therapy, with direct observation of res-
ponse and eradication of residual local disease by planned
locoregional surgery 3-6 months later (Forrest et al., 1986;
Anderson et al., 1989). This method of treatment has allowed
the study of the concentration of ER, both before and after
systemic therapy, within the same tumour mass (primary
tumour).
Methods
Patient population
We attempted to measure oestrogen receptor concentration,
both before and after systemic therapy, in 88 patients with
large (mean clinical diameter >4 cm) operable (T2 or T3, No
or N1 and MO) cancers of the breast: one patient had two
tumours and thus there was a total of 89 tumours. In 26
patients, the tumour specimen was inadequate (see below) on
one or more occasions: this left 62 patients (with 63 tumours)
for study. These patients form part of a larger series which
will be reported in full elsewhere (Anderson et al., in prepara-
tion).
Twenty-six patients were premenopausal and 36 were post-
menopausal in that it was greater than one year since their
last menstrual period. The mean age of the population was
53 years (range 34-69).
Method
Before administration of systemic therapy, tumour was
obtained from 62 patients for histological and biochemical
studies, including ER assay, by an incisional wedge biopsy
performed under general anaesthesia. Forty-one patients with
ER- moderate/rich tumours (ER >20 fmol mg'I cytosol
protein) and four with ER-poor/negative tumour
(ER <20 fmol mg-' protein) were initially treated by endo-
crine therapy. Ovarian function was ablated in
premenopausal patients either surgically (n = 4), or
medically, using the luteinising hormone releasing hormone
agonist, goserelin (ICI 118630 or zoladex, 3.6 mg sub-
cutaneous depot preparation at 28-day intervals, n = 16).
Tamoxifen (20 mg per day, n = 3) or an aromatase inhibitor
(aminoglutethimide 500 mg plus 40 mg hydrocortisone
acetate, n = 7, or 4-hydroxyandrostenedione, Ciba-Geigy
CGP 32349, 250 mg intramuscular injection at 14-day inter-
vals, n = 15) were the endocrine therapies used in post-
menopausal patients. Thirteen patients who failed to respond
to endocrine therapy subsequently went on to receive
cytotoxic therapy (four cycles of 'CHOP': cyclophosphamide
1 g m-2, adriamycin 50 mg m2, vincristine 1.4 mg m2 and
oral prednisolone, 40 mg per day for 5 days, at 21-day
intervals).
A further 17 patients with tumours of low ER concentra-
tion (<20 fmol mg-' cytosol protein) were given cytotoxic
therapy (CHOP x 4) as initial treatment.
During treatment, the tumour was measured weekly by
clinical examination and monthly by mammographic assess-
ment. Response was classified on the basis of linear regres-
sion analysis (Apple Macintosh Statview program) of
changes in clinical tumour diameter as previously described
(Anderson et al., 1989) but the results have been presented in
terms of a calculated tumour volume in order to give a better
indication of 'tumour bulk'. Three response categories were
defined: significant regression, when the probability that
significant reduction in tumour size was >95%; progression,
when there was a significant increase in tumour size or signs
of local advancement; and no change, when no significant
difference in tumour size could be demonstrated.
Following 3 months of systemic therapy (6 months when
patients received both endocrine and cytotoxic therapies),
patients proceeded on to mastectomy and axillary lymph-
node clearance. When residual tumour was present within the
mastectomy specimen, a portion was selected for ER assay
by the pathologist.
In both pre- and post-treatment specimens, a section was
cut from the face of the tissue portion used for receptor
analysis, fixed in formol-saline and stained with haematoxylin
and eosin to permit histopathological confirmation of the
presence of tumour. Twenty-six patients in whom either the
pre- or post-treatment specimen contained <10% tumour, as
assessed by the pathologist, have been excluded from the
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study: these include, for example, 11 patients who achieved a
complete clinical response to chemotherapy. Thus of the
whole group, both pre- and post-treatment specimens were
available in 62 patients (63 tumours).
Correlation ofchanges in ER concentration with changes in
histology
To examine the correlation between any changes in ER
concentration and histopathology, 12 paired (pre- and post-
treatment) tumour samples were independently examined by
Dr T.J. Anderson, Department of Pathology, and graded as
to whether they showed major differences in morphology or
not between the pre- and post-treatment specimens.
Statistical analysis
The relationship between the pre- and post-treatment speci-
men ER concentrations was examined using the paired t test
after logarithmic transformation of the data.
Determination ofoestrogen receptor activity
Oestrogen receptor activity was determined by saturation
analysis (Hawkins et al., 1975, 1981) on both the pre-
treatment biopsy and post-treatment tumour from the
mastectomy specimen. Quality control samples, processed
2-4 times per week, consisted of pools of finely divided
uterine tissue and, on occasion lyophilised powders. The
dissociation constant of binding (Kd) and receptor site con-
centration (PO) were evaluated by Scatchard analysis (1949).
The soluble protein concentration in each tumour extract
was determined by the method of Bradford (1976) using
bovine serum albumin as a standard. Five quality controls of
known value (three albumin, two mixed standard, Sigma
540-10) were also processed; assays in which the quality
controls deviated by more than 10% from the expected
values were repeated. Ultimately the receptor content of each
tumour was expressed as fmol binding sites per mg soluble
protein (PO protein).
The overall intra-assay precision on a pool of minced
uterine tissue was 15.4% (n = 5). Inter-assay precision on
lyophilised powders (no homogenisation step) was 17.8%
(n = 10) at low levels (27 fmol mg-' protein) and 11.7% at
higher levels (90 fmol mg-' protein); on two pools of minced
uterine tissue (including homogenisation) it was 25.5%
(n = 144) at low levels (48 fmol mg-' protein) and 17.0%
(n = 48) at a higher level (111 fmol mg-' protein).
Results
Changes in ER concentration according to type ofsystemic
therapy
The changes in ER concentration in the tumours from the 62
patients, separated into groups according to mode of treat-
ment, are shown in Table I. Although the changes in individ-
ual tumours varied considerably, even within one treatment
group (Figure 1), there was no significant change in receptor
concentration in patients treated by surgical or medical
oophorectomy, aromatase inhibitors, chemotherapy or both
cytotoxic and endocrine therapies. Only the three patients
treated with tamoxifen showed a significant (99%) fall in ER
concentration after 3 months.
Changes in ER concentration according to response to therapy
When the patients were separated into those who achieved a
significant regression to systemic therapy and those who did
not, no significant change in the receptor concentration was
found in either group (Table II). Six of the 62 patients have
been excluded from this table because they were on tamox-
ifen, shown above to influence receptor levels.
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Figure 1 The changes in oestrogen receptor concentration in 63
large, operable primary breast cancers: receptor concentration
was assayed by ligand-binding assay in a pretreatment wedge
biopsy and again, after systemic therapy for 3 or 6 months, in
tumour removed at mastectomy. Each point represents a single
assay: the lines drawn join pre- and post-treatment specimens
from the same patient. Only the change seen in patients on
tamoxifen is significant (paired t test, P<0.05).
Table I Changes in receptor concentration in large primary breast tumours during
systemic therapy
Oestrogen receptor conc. (fmolmg-' protein)a
Treatment group Pre-treatment Post-treatment Difference Sig.b
Surgical/medical 49 60 1.2 n.s.
oophorectomy ± 3.0
(n = I I)C
Aromatase 163 163 1.1 n.s.
inhibitors ± 2.3
(n= 19)
Tamoxifen 186 2 68 P<0.05
(n = 3) ±3.6
Chemotherapy 4 4 1.0 n.s.
(n = 17) ±3.5
Endocrine & 24 18 1.3 n.s.
chemotherapy' ± 2.1
(n= 13)
aGeometric mean calculated after logarithmic transformation of (receptor
concentration + 1); ± one standard deviation. bSignificance calculated from paired t test
on log-transformed data. Cn = number oftumours. For the group treated with aromatase
inhibitors, 18 patients were treated, one patient having two tumours. dPatients on
tamoxifen have been excluded.GESTROGEN RECEPTOR LEVEL DURING THERAPY 879
Table II Changes in receptorconcentration and tumourvolume inlargeprimary tumoursaccording to response tosystemic
therapy
Response Pre-treatment Post-treatment
group Treatment valuea valuea Difference Significance
Oestrogen receptor concentration (fmolmg' protein)
Regression (n = 33)C
Endocrineb (17) 102 127 1.26 n.s.
±2.96
Chemotherapy (13) 3 4 1.15 n.s.
±2.69
Endob+ Chemo (3) 43 34 - 1.26 n.s.
±2.89
No significant regression (n = 23)
Endocrineb (11) 79 70 -1.14 n.s.
+3.08
Chemotherapy (4) 8 6 -1.36 n.s.
i7.66
Endob + Chemo (8) 33 24 -1.38 n.s.
+2.63
Clinical tumour volume (cm3)'
Regression all 53.4 9.0 -6.86 P<0.001
± 2.93
No significant regression all 34.7 28.4 -1.25 P<0.005
+1.36
aGeometric means calculated after logarithmic transformation ± one standard deviation. bPatients on tamoxifen have been
excluded (n = 6). 'n = number oftumours, one patient having two tumours. dTumour diameter was measured and response
was classified as described previously (Anderson et al., 1989). The results were converted to a tumour volume to give a better
indication of tumour bulk, using the formula 4/3wr3, where r = mean tumour radius.
As a control, the change in tumour volume for these two
response groups was also examined. As expected, the group
of patients showing significant regression, taken as a whole,
exhibited a highly significant decrease in tumour volume.
Although the remaining patients individually did not show a
significant reduction in tumour volume, as a group they also
exhibited a small decrease.
Examination of the relationship between changes in ER
and change in tumour volume in individual patients (data
not shown) equally did not reveal any consistent pattern.
Changes in ER concentration in relation to tumour morphology
Although most treatments were, on average, without
significant effect on ER concentration, in some individual
patients there were large changes in tumour ER. In order to
see if these related to tumour heterogeneity and sampling, the
histological sections from 12 paired (pre- and post-treatment)
tumour specimens were examined by the pathologist, in the
absence of any knowledge of the ER concentration.
Of six paired tumour specimens showing a 'large' change
in receptor concentration, four showed major differences in
morphology between the pre- and post-treatment specimens.
By contrast, none of the six paired specimens from patients
showing little or no change in ER concentration exhibited
any striking difference in histopathological appearance.
Discussion
This study has demonstrated that, on average, tumour ER
concentration is little changed by most forms of systemic
therapy. Large changes in tumour ER concentration in indi-
vidual patients were probably related to tumour
heterogeneity (Hawkins et al., 1977a; Van Netten, 1985; Sen-
banjo et al., 1986). Patients on tamoxifen, however, did show
a marked fall in receptor concentration during therapy; this
was almost certainly due to interference by tamoxifen or its
metabolites in the ligand-binding assay, as noted by Hull et
al. (1983). In the present study, patients treated by medical or
surgical oophorectomy showed only a slight, but insignificant
rise in tumour ER concentration. In a large number of
patients with fibroids, treated with the LHRH agonist,
zoladex, however, a similar but significant rise in the concent-
ration of ER in the uterine tissues has been observed (Lums-
den et al., 1989).
Previous studies in patients with breast cancer (Taylor et
al., 1982; Hamm & Allegra, 1988; Toma et al., 1986) and in
experimental animals (Vignon & Rochefort, 1976; Hawkins
et al., 1977b; Cho-Chung et al., 1978) have shown a decrease
in receptor concentration after endocrine manipulation or, as
in the present study, no consistant change (Hull et al., 1983;
Mobbs et al., 1987). The conflicting results,in human breast
cancer may derive from the inclusion of patients on tamox-
ifen (Taylor et al., 1982), which causes a marked apparent
reduction in ER concentration (this study and Hull et al.,
1983) or from the difficulties in comparing different tumour
deposits (Taylor et al., 1982; Hamm & Allegra, 1988).
In summary, ER concentration in breast tumours changed
little after most common forms of systemic therapy, even in
regressing tumours. Thus, in general, a marked change in ER
concentration does not appear to be a component of the
mechanism by which tumours are initially influenced by
systemic therapy.
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